Metabolomics company Metabolon just raised about $5 million in equity from four investors, according to a recent regulatory filing. The metabolomics company plays in the precision medicine space, providing phenotyping tech that can, say, determine how an individual reacts to a drug.
There were whispers about a year ago that Metabolon was readying itself for IPO, but that has yet to happen. The Wall Street Journal wrote at the time:
The company generated about $25 million in revenue last year, people familiar with the IPO planning said.
It is backed by roughly $50 million in private funding, including from Aurora Funds Inc., Fletcher Spaght Ventures LP, Syngenta Ventures, Sevin Rosen Funds, Harris & Harris Group Inc. and Keating Capital Inc.
This new round is the latest Metabolon has raised since 2013. The company also made some waves a year ago when it announced it had teamed up with J. Craig Venter’s well-funded genomics company meant to elongate human life – Human Longevity Inc.
Calls to Metabolon to learn what the new funding will be used for have yet to be returned; stay tuned for more.
